Saturday, May 14, 2022
No Result
View All Result
Medical Finance
  • Home
  • News
  • Interviews
  • Mediknowledge
  • Insights From Industry
  • Thought Leaders
  • Coronavirus
  • Whitepapers
  • Home
  • News
  • Interviews
  • Mediknowledge
  • Insights From Industry
  • Thought Leaders
  • Coronavirus
  • Whitepapers
No Result
View All Result
Medical Finance
No Result
View All Result
Home Coronavirus

Children with severe COVID-19 show low mucosal neutralizing activity against SARS-CoV-2

by Medical Finance
in Coronavirus
Study: Systemic and Lower Respiratory Tract Immunity to SARS-CoV-2 Omicron and Variants in Pediatric Severe COVID-19 and Mis-C. Image Credit: FamVeld/Shutterstock
9
SHARES
99
VIEWS
Share on FacebookShare on Twitter

Mucosal immunity is vital to respiratory barriers against infections, such as the circulating severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

However, little is known about mucosal antibodies to this virus in children with coronavirus disease 2019 (COVID-19), including the uncommon complication of multisystem inflammatory syndrome in children (MIS-C).

Study: Systemic and Lower Respiratory Tract Immunity to SARS-CoV-2 Omicron and Variants in Pediatric Severe COVID-19 and Mis-C. Image Credit: FamVeld/ShutterstockStudy: Systemic and Lower Respiratory Tract Immunity to SARS-CoV-2 Omicron and Variants in Pediatric Severe COVID-19 and Mis-C. Image Credit: FamVeld/Shutterstock


A new study examines neutralizing responses to the ancestral variant of this virus, as well as against the later variants of concern.

Introduction

During the initial phase of the pandemic, children were considered to be largely spared, with low infection and transmission rates. However, a significant minority of infected children may have severe disease, or may develop post-infectious sequelae such as MIS-C.

Omicron emerged in late 2021, and is known to have a large number of mutations in the spike protein, accompanied by resistance to neutralizing antibodies induced by COVID-19 vaccination or natural infection with other variants.

For this reason, the current study, published in the journal Vaccines, looks at lower respiratory tract mucosal immunity in children, in an attempt to understand how this can neutralize emerging variants of the virus in this age group.

Hospitalized children with severe acute infection or MIS-C were included in this study. Their neutralizing antibody levels in the trachea were compared with the systemic immunity generated against the ancestral strain, and against five variants of concern (VOC), the Alpha, Beta, Gamma, Delta and Omicron, as well as variants of interest (VOI) Epsilon, Iota and Kappa. The tracheal secretions in children are considered the equivalent of bronchoalveolar secretions in this study, since bronchoalveolar lavage (BAL) is hardly ever carried out in children with this infection.

The study data came from the Overcoming COVID-19 Network study, focused on severe complications of pediatric COVID-19 at Boston Children’s Hospital. Patients with severe infection were tested using both plasma samples and endotracheal aspirates, but the latter was obviously not available for children with mild infection. None of the subjects had immunosuppression, terminal lung disease, or life support limitations.

There were five paired samples of plasma and endotracheal aspirate (ETA) from severe COVID-19 patients, and five from MIS-C patients. All were before the newer VOCs or VOIs emerged. The median age was 10 years, and the median hospital admission duration was ~14 days. There were no deaths before discharge.

Findings

All the plasma samples contained neutralizing antibodies to the ancestral SARS-CoV-2 variant, without significant differences between the variants. With severe COVID-19, the levels were 4- to 11-fold lower against the Alpha VOC, but 20-fold, 30-fold and 50-fold lower against the Gamma, Beta and Omicron VOCs. However, for MIS-C, the titers were lower for all variants.

With pediatric COVID-19, total antibody levels, immunoglobulin (Ig)M, IgG and IgA, were all raised in plasma compared to ET levels, by 40-fold for IgM vs 54-fold for IgG and IgA. Conversely, with MIS-C, IgM antibody levels were raised by 44-fold in ETA, but IgG by ~170-fold and IgA by 75-fold.

ETA neutralizing antibodies were found in only two COVID-19 vs 3 MIS-C patients, against the ancestral strain. The patient with the highest titer had been intubated for 8 days, of which the sample was taken on the fourth day. This sample showed high activity against all variants.

However, for other samples, neutralizing titers were lower against the variants. In fact, there was a 2-35-fold drop against all SARS-CoV-2 variants compared to the plasma samples, though the levels in the two sample types were correlated for neutralizing activity.

Implications

The results show that children with severe COVID-19 or MIS-C have weak neutralizing activity in the respiratory mucosa of the lower tract, against all variants of the virus. This leaves them vulnerable to newer variants. In fact, children have been hospitalized in increasing numbers with the emergence of Omicron, as explained by the weak neutralizing titer in the respiratory mucosa.

The antibody escape seen with the newer variants could be due to the mutational alteration in antibody-binding sites on the spike, a higher binding affinity for the angiotensin-converting enzyme 2 (ACE2) receptor, or an increase in the positive charge on the virus spike, increasing the binding to the host cell’s negatively charged surface.

Again, the collection of the ETA samples occurred early in the course of the disease, which may account for the lower neutralizing titer, which is in contradiction to an earlier study that showed high activity against the ancestral variant after day 4 from symptom onset.

More studies should be undertaken to confirm low neutralizing antibody levels in the lower respiratory tract in children, as this could lead to long Covid and other debilitating sequelae.

Low mucosal immunity against Omicron and other variants suggest that these children can be re-infected with evolving variants”, explained the researchers.

Vaccines that are very safe as well as associated with the induction of mucosal immunity in the upper and lower respiratory tract would help, “to provide both protection from disease as well as reduce viral titers in respiratory tract and limit viral transmission to curtail the spread of SARS-CoV-2”, the researchers confirmed.

Total
0
Shares
Share 0
Tweet 0
Pin it 0
Share 0
Medical Finance

Medical Finance

Related Posts

Researchers analyze the role of self-deception in everyday life

New COVID-19 vaccine proven to be safe and effective in late-stage clinical testing

by Medical Finance
May 14, 2022
0

A COVID-19 vaccine developed at the University of Washington School of Medicine has proven safe and effective in late-stage clinical...

Omicron variant found to be much less sensitive to neutralizing antibodies than Delta

Pharmacies are turning away immunocompromised patients seeking 4th covid shot

by Medical Finance
May 14, 2022
0

Patients with weakened immune systems — who are at high risk from covid-19 — say pharmacies are turning them away...

Study identifies cellular receptors for alphaviruses shared across mosquitoes, humans, and animals

Drug-resistant mold found to be spreading and infecting susceptible people’s lungs

by Medical Finance
May 14, 2022
0

A new study led by Imperial College London finds that drug-resistant mold is spreading from the environment and infecting susceptible...

Study: Using Survey Data to Estimate the Impact of the Omicron Variant on Vaccine Efficacy against COVID-19 Infection. Image Credit: G.Tbov/Shutterstock

Scientists find reduced vaccine efficacy against Omicron in South Africa and 50 other countries

by Medical Finance
May 14, 2022
0

In a recent study posted to the medRxiv* pre-print server, a team of researchers evaluated the impact of severe acute...

Study: SARS-CoV-2 vaccination can elicit a CD8 T-cell dominant hepatitis. Image Credit: NIAID

COVID-19 vaccine can elicit a distinct T cell-dominant immune-mediated hepatitis

by Medical Finance
May 14, 2022
0

In a recent study published in the Journal of Hepatology, researchers reported that the coronavirus disease 2019 (COVID-19) vaccination could...

Study: High vaccination coverage slows down genetic diversity of SARS-CoV-2. Image Credit: solarseven / Shutterstock

As vaccination coverage increases, SARS-CoV-2 genetic diversity decreases

by Medical Finance
May 14, 2022
0

In a recent letter to the editor published in the Journal of Infection, researchers from the Chinese PLA Center for...

Next Post
What are the benefits of Irish Life Sciences’ new 2.2 mL square well ‘V’ bottom plate?

Combating infectious diseases with reagent banks

New research may help better understand the causes of human diseases

0 0 votes
Article Rating
Subscribe
Login
Notify of
guest
guest
0 Comments
Inline Feedbacks
View all comments

Support

  • Contact
  • Disclaimer
  • Home
  • Privacy Policy
  • Terms And Conditions

Categories

  • Coronavirus
  • Insights From Industry
  • Interviews
  • Mediknowledge
  • News
  • Thought Leaders
  • Whitepapers

More News

  • Study: Identification of a conserved drug binding pocket in TMEM16 proteins. Image Credit: Irina Anosova/Shutterstock
    Study reveals that 1PBC and niclosamide bind the same drug-binding pocket
  • Study: Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19: A Randomized Clinical Trial. Image Credit: wavebreakmedia / Shutterstock.com
    Study evaluates efficacy of sarilumab in severe/critical COVID-19 patients
  • Home
  • Privacy Policy
  • Contact
  • Disclaimer
  • Terms And Conditions

© 2022 Medical Finance - Latest Financial and Business News

No Result
View All Result
  • Interviews
  • Mediknowledge
  • News
  • Insights From Industry
  • Coronavirus
  • Thought Leaders
  • Whitepapers
wpDiscuz
0
0
Would love your thoughts, please comment.x
()
x
| Reply